|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM15177515X |
| 003 |
DE-627 |
| 005 |
20250205232951.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0506.xml
|
| 035 |
|
|
|a (DE-627)NLM15177515X
|
| 035 |
|
|
|a (NLM)15507392
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kalish, Richard S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Minocycline inhibits antigen processing for presentation to human T cells
|b additive inhibition with chloroquine at therapeutic concentrations
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.12.2004
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The ability of minocycline to inhibit processing of tetanus toxoid (TT) for presentation to human T cells was tested. Peripheral blood antigen presenting cells (APC) were incubated with TT before or after addition of test compounds for 4 h. APC were then fixed with paraformaldehyde, and added to autologous TT-responsive T cell lines for a proliferation assay. Minocycline (0.1-0.4 mM) gave significant inhibition of T cell response to TT and was equivalent to chloroquine. Inhibition was not observed when TT was incubated with APC before minocycline, indicating that presentation of preprocessed antigen was not inhibited. Minocycline, doxycycline, and tetracycline all inhibited the proliferation of PBMC to TT. The combination of minocycline and chloroquine resulted in additive inhibition at clinically relevant levels of both drugs (3.7 microM). This study suggests a novel immunosuppressive mechanism for minocycline, as well as possible additive anti-inflammatory effect when combined with chloroquine or hydroxychloroquine
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Tetanus Toxoid
|2 NLM
|
| 650 |
|
7 |
|a Chloroquine
|2 NLM
|
| 650 |
|
7 |
|a 886U3H6UFF
|2 NLM
|
| 650 |
|
7 |
|a Minocycline
|2 NLM
|
| 650 |
|
7 |
|a FYY3R43WGO
|2 NLM
|
| 650 |
|
7 |
|a Doxycycline
|2 NLM
|
| 650 |
|
7 |
|a N12000U13O
|2 NLM
|
| 700 |
1 |
|
|a Koujak, Susan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 113(2004), 3 vom: 12. Dez., Seite 270-7
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:113
|g year:2004
|g number:3
|g day:12
|g month:12
|g pages:270-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 113
|j 2004
|e 3
|b 12
|c 12
|h 270-7
|